Search the Newsreel

Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $965 From $968, Maintains Buy Rating

Goldman Sachs has adjusted its price target for Regeneron Pharmaceuticals (REGN) to $965 from $968 while maintaining a "Buy" rating. The company specializes in developing and selling drugs for ophthalmologic, inflammatory diseases, and cancers, with significant revenue from collaboration agreements. Regeneron also has a …

Regeneron Pharmaceuticals (REGN) Jefferies Global Healthcare Conference Summary

This article summarizes Regeneron Pharmaceuticals' recent Jefferies Global Healthcare Conference presentation. Key updates include promising oncology program data for PD-1/LAG-3 in melanoma and NSCLC, progress with CD28 bispecifics for solid and prostate tumors, and advances in systemic C5 inhibition for geographic atrophy and Factor …

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN

The DJS Law Group has announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) for alleged securities law violations. The lawsuit claims Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, which ultimately failed to meet its primary endpoint. Shareholders who …

REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

Faruqi & Faruqi, LLP is reminding investors of the September 14, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo …

Will Pediatric Casgevy Expansion and Canadian ALYFTREK Talks Change Vertex Pharmaceuticals' (VRTX) Narrative?

U.S. regulators recently expanded approval of Vertex Pharmaceuticals' gene-editing therapy Casgevy for pediatric patients as young as 2 years old. Concurrently, Canada's pan-Canadian Pharmaceutical Alliance has initiated discussions for public reimbursement of Vertex's cystic fibrosis therapy ALYFTREK. These developments are viewed as crucial for …

Regeneron (REGN) Stock Looks Discounted As It Holds A 24% Gain

Regeneron Pharmaceuticals (REGN) has seen a 24.1% return over the past year and appears undervalued based on broad valuation checks and Simply Wall St's framework, despite some recent pipeline trial setbacks and a notable R&D charge. The stock's current P/E ratio of 15.6x is …

REGN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc.

Robbins LLP has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. on behalf of investors who purchased shares between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron misled investors by making positive statements about its Phase III Fianlimab-Libtayo Study …

Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In?

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Regeneron Pharmaceuticals, Inc. Common Stock and Sets a Lead Plaintiff Deadline of September 14, 2026

Levi & Korsinsky, LLP has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. on behalf of investors who purchased common stock between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, …

Regeneron Investor Sues Over Cancer Drug Trial Miss, Stock Drops

An investor has filed a proposed class action lawsuit against Regeneron Pharmaceuticals Inc., alleging the company and its executives misrepresented the progress of a phase III clinical trial for a skin cancer drug. The lawsuit claims Regeneron overhyped the drug combination's potential despite a …

Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit

Robbins LLP has notified investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of stockholders who purchased shares between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron misled investors about the viability …

How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story

Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)

Regeneron Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement

Regeneron (REGN) Q1 2026 Earnings Transcript

Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q1 Earnings?

Regeneron (REGN): Buy, Sell, or Hold Post Q4 Earnings?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think